Wednesday, July 03, 2024
QuantHealth, a leading AI-driven clinical trial design company, has announced a strategic partnership with OMNY Health, a prominent healthcare data ecosystem facilitating compliant cross-industry data sharing.
This collaboration aims to leverage OMNY Health's extensive network of de-identified data to unlock new insights for clinical trials, evidence-based practice, and medical research.
QuantHealth serves several of the top global pharmaceutical companies and plans to integrate diverse electronic health records (EHRs) into organized, de-identified research data products provided by OMNY Health.
OMNY Health's comprehensive data portfolio supports various analytic needs in life sciences innovation, addressing disparities in clinical trials and bridging demographic information gaps in drug discovery and development.
Through this partnership, QuantHealth aims to expedite drug development by utilizing AI technology trained on a dataset of 350 million patients.
Their AI capabilities enhance clinical trial timelines, mitigate risks, and identify patient sub-populations likely to respond positively to treatments.
The partnership's focus on leveraging quality data and enhancing simulated clinical trials. He highlighted the potential for this collaboration to revolutionize research and development by providing high-quality insights to life sciences partners.
OMNY Health's CEO, underscored their mission to facilitate secure data sharing, enabling transformative partnerships that accelerate drug development and optimize clinical trials.
The collaboration reflects OMNY Health's commitment to breaking down data silos and driving advancements in therapeutic outcomes and patient care through data-driven solutions.
This partnership follows QuantHealth's recent strategic investments and underscores their commitment to advancing pharmaceutical programs through innovative AI-driven approaches.
Founded in 2020, QuantHealth continues to shape the future of clinical trials by predicting outcomes, enhancing drug efficacy assessments, and delivering real-world evidence to support medical advancements.
Source: businesswire.com
